Media Center
In the media
Ability Pharma receives the acknowledgement from Cerdanyola Empresarial
Parc UAB newsletter
22/11/2019
Ability reinforces the direction and rises 2 million euros from Inveready and Everis
Expansión
13/09/2019
A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer
RAC1
06/06/2019
The partner of AbilityPharma in China starts clinical trials with the licensed drug
Expansión
04/02/2019
AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA
Expansión
08/11/2018
TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech
Innovaspain
26/09/2018
LATEST NEWS
09.06.2020
News
AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020
News
AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019
News
AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019
News
Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019
News
Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019
News
Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018
News
AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018
News
Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018
News
Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
